TransCode Therapeutics, Inc.
$8.88
▼
-1.04%
2026-04-21 09:11:01
www.transcodetherapeutics.com
NCM: RNAZ
Explore TransCode Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$8.07 M
Current Price
$8.88
52W High / Low
$22.03 / $6.08
Stock P/E
—
Book Value
$1.71
Dividend Yield
—
ROCE
-334.68%
ROE
-17.63%
Face Value
—
EPS
$-236.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
1.5
Debt / Equity
-0.02
Current Ratio
1.6
Quick Ratio
2.56
Forward P/E
-13.68
Price / Sales
—
Enterprise Value
$4.69 M
EV / EBITDA
-0.28
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Creative Medical Technology Holdings, Inc. | $2.26 | — | $9.13 M | — | -81.64% | -86.47% | $6.25 / $1.5 | $2.03 |
| 2. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
| 3. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
| 4. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 5. | Editas Medicine, Inc. | $3.57 | — | $349.4 M | — | -70.81% | -1.98% | $4.54 / $1.23 | $0.28 |
| 6. | Bolt Biotherapeutics, Inc. | $5.15 | — | $9.09 M | — | -71.68% | -79.75% | $9.25 / $3.91 | $13.8 |
| 7. | Century Therapeutics, Inc. | $2.34 | — | $467.28 M | — | -5.16% | -5.98% | $3.04 / $0.43 | $1.82 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -4.54 M | -4.07 M | -2.82 M | -4.61 M | -2.15 M |
| Net Profit | -4.86 M | -4.28 M | -12.09 M | -5.92 M | -2.32 M |
| EPS in Rs | -5.3 | -4.66 | -13.18 | -6.45 | -2.53 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -15.14 M | -18.5 M | -17.55 M | -5.87 M |
| Net Profit | -16.75 M | -18.55 M | -17.56 M | -6.84 M |
| EPS in Rs | -18.27 | -20.23 | -19.16 | -7.46 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 7.29 M | 5.17 M | 7.59 M | 22.94 M |
| Total Liabilities | 9.31 M | 3.53 M | 4.35 M | 2.53 M |
| Equity | -2.02 M | 1.64 M | 3.24 M | 20.4 M |
| Current Assets | 7.09 M | 4.46 M | 7.38 M | 22.73 M |
| Current Liabilities | 2.77 M | 3.49 M | 4.35 M | 2.53 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -13.34 M | -18.07 M | -15.76 M | -5.27 M |
| Investing CF | -0.02 M | -0.04 M | -0.1 M | -0.25 M |
| Financing CF | 16.4 M | 15.91 M | 0.01 M | 25.52 M |
| Free CF | -13.36 M | -18.11 M | -15.86 M | -5.52 M |
| Capex | -0.02 M | -0.04 M | -0.1 M | -0.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 9.66% | -5.59% | -156.67% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-05-15 | 1:0.0357143 |
| 2024-12-04 | 1:0.030303 |
| 2024-01-16 | 1:0.025 |
| 2023-05-23 | 1:0.05 |